Promising Findings in HER2-Positive Metastatic Breast Cancer Treatment

Introduction to HER2-Positive Breast Cancer

A recent study highlights the effectiveness of a combination treatment involving tucatinib, trastuzumab, and capecitabine for patients with HER2-positive metastatic breast cancer. This subtype of breast cancer is known for its aggressive nature compared to other forms.

Overview of Tucatinib

Tucatinib is an oral tyrosine kinase inhibitor specifically targeting a distinct region of the HER2 protein. Researchers aimed to evaluate how tucatinib, when combined with trastuzumab and capecitabine, improves progression-free survival in affected patients.

Study Design and Methodology

The study, published in the New England Journal of Medicine, utilized a randomized, double-blind trial format. Researchers enrolled over 600 patients, assigning them in a 2:1 ratio to receive either 300 mg of tucatinib twice daily or a placebo. In total, 410 patients received the tucatinib combination, while 202 were given the placebo. Participants underwent CT scans or MRIs every six weeks for 24 weeks, with laboratory tests conducted every three weeks to assess disease response and progression.

Results of the Study

The findings revealed that the risk of disease progression or death was 46% lower in the tucatinib combination group compared to the placebo group. After one year, the progression-free survival rate was 33.1% for those receiving the combination treatment, in contrast to 12.3% for the placebo group. The median progression-free survival was reported as 7.8 months for the tucatinib group versus 5.6 months for the placebo group.

At the two-year mark, overall survival rates were 44.9% for the tucatinib combination group compared to 26.6% for the placebo group, with median survival durations of 21.9 months and 17.4 months, respectively. Additionally, the risk of death was found to be 34% lower in the tucatinib group.

Adverse Effects and Patient Discontinuation

The most frequently reported adverse effects in the tucatinib combination group included diarrhea, nausea, fatigue, and vomiting, as well as elevated levels of alanine aminotransferase and aspartate aminotransferase. These side effects led to 5.7% of patients discontinuing tucatinib, while 3% of the placebo group ceased treatment. Serum creatinine levels were notably higher in the tucatinib group at 13.9%, compared to just 1.5% in the placebo group.

Conclusion

The study’s results indicate that tucatinib represents a safe and effective oral treatment option for patients with HER2-positive breast cancer, yielding encouraging outcomes.

Written by Katrina F. Zafer, BSc

References

Murthy, R. K., Loi, S., Okines, A., Paplomata, E. (2019). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1914609

Mayo Clinic – https://www.mayoclinic.org/breast-cancer/expert-answers/faq-20058066

Image by marijana1 from Pixabay